



## Oncolytic Viruses as Immunotherapeutic Agents

Guest Editor:

**Dr. Nadine Van Montfoort**

Department of Medical Oncology,  
Oncode Institute, Leiden  
University Medical Center, 2333  
ZA Leiden, The Netherlands

Deadline for manuscript  
submissions:

**closed (1 May 2024)**

### Message from the Guest Editor

Dear Colleagues,

In these challenging times, where pathogenic viruses such as SARS-CoV2 are at the center of attention, it is important to provide a platform for viruses that can help in treating cancer. These oncolytic viruses are non-pathogenic but instead they have the unique ability to specifically counteract malignant cells. One of the key features of oncolytic viruses is that they can create an immune-stimulatory inflammation in the tumor micro-environment. Therefore, oncolytic virotherapy can be classified as a novel type of targeted immunotherapy. An increasing amount of data suggests that oncolytic viruses can enhance efficacy of immunotherapy in resistant tumors. Still, many questions remain unanswered.

In this Special Issue, we welcome original studies and reviews about oncolytic virus-host immune interactions, viro-immunotherapy mechanisms, and novel combinatorial approaches.

Dr. Nadine Van Montfoort

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Eric O. Freed

Director, HIV Dynamics and  
Replication Program, Center for  
Cancer Research, National  
Cancer Institute, Frederick, MD  
21702-1201, USA

## Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, **PubAg**, **AGRIS**, and **other databases**.

**Journal Rank:** JCR - Q2 (*Virology*) / CiteScore - Q1 (*Infectious Diseases*)

## Contact Us

*Viruses* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/viruses](http://mdpi.com/journal/viruses)  
[viruses@mdpi.com](mailto:viruses@mdpi.com)  
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)